SCHEMBL676124

SCHEMBL676124

O=[N+]([O-])c1ccccc1-c1ccc2[nH]c3nc(Cl)ccc3c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
ALDH1A1 P00352 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
KMT2A Q03164 2/20 0.41
ADORA1 P30542 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GMNN O75496 1/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
ADORA2A P29274 1/20 0.41
CYP2C19 P33261 1/20 0.41
MTOR P42345 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL675109 0.87 PTPN1 (0.45) ALDH1A1TDP1KMT2AADORA1GUSB
SCHEMBL19022524 0.82 ALDH1A1 (0.56) ALDH1A1TDP1KMT2AADORA1LMNA
SCHEMBL674242 0.81 ALDH1A1 (0.41) ALDH1A1TDP1KMT2APKMPTGES
SCHEMBL676125 0.81 GRIN2D (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL19022533 0.79 KMT2A (0.56) ALDH1A1TDP1KMT2ALMNAHSD17B10
SCHEMBL675938 0.78 ALK (0.48) ALDH1A1TDP1KMT2AKDM4ELMNA
SCHEMBL675919 0.77 KDM4E (0.54) KMT2AADORA1KDM4EGMNNLMNA
SCHEMBL674677 0.75 ALK (0.50) ALDH1A1TDP1KMT2ACHEK1WEE1
SCHEMBL19021724 0.75 GABRA1 (0.49) ALDH1A1TDP1KMT2AKDM4EGMNN
SCHEMBL31453720 0.72 ALDH1A1 (0.61) ALDH1A1TDP1KMT2AADORA1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 GRIN2D 4133/4885GRIN3B 3971/4885GRIN1 3167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.